Preliminary of COVAXIN and ZyCov-D marks ‘start of the end’, says researcher in article

Preliminary of COVAXIN and ZyCov-D marks ‘start of the end’, says researcher in article


  • Post By : Kumar Jeetendra

  • Source: PTI

  • Date: 06 Jul,2020

The announcement of COVAXIN from Bharat Biotech and also ZyCov-D by Zydus Cadila is the”silver line in the dark clouds”, this post by T Venkateswaran, who is a scientist with Vigyan Prasar, ” said.

“The nod supplied by the Drug Controller General of India, CDSCO (the Central Drugs Standard Control Organisation) to its behavior of the human trial for those vaccines, marks the beginning of the ending,” the article stated.

In recent years, India has emerged as a significant vaccine manufacturing hub and Indian manufacturers account for 60 per cent of vaccine supplies built to UNICEF.

“The vaccine to its publication coronavirus could possibly be manufactured anywhere in the world, but without Indian manufacturing companies involved the production of required levels isn’t planning to be achievable,” the essay said.

It said at the international level, more than 140 candidate studies are under various stages of development.

The article said that along with the two Indian vaccines, COVAXIN and ZyCov-D, around the world, 11 out of 140 vaccine candidates have entered human trials.

One of the leading candidates is AZD1222 made by the Jenner Institute at the University of Oxford and licenced to AstraZeneca, a British-Swedish multinational pharmaceutical and biopharmaceutical firm headquartered in Cambridge, England.

The MRNA-1273 vaccine developed by the Kaiser Permanente Washington Health Research Institute, Washington, and taken up for production from US-based Moderna pharmaceutical, is only a step behindthe article states.

These two firms have already inked an agreement with Indian manufacturers such as production of their COVID-19 vaccines,” it said.

Indian associations are engaged in development and research for the development of vaccines in India.

Aiming to establish an native COVID-19 vaccine by August 15, the Indian Council of Medical Research (ICMR) had written to select medical institutions and hospitals to fast-track clinical trial approvals for its vaccine offender COVAXIN being developed in cooperation with Bharat Biotech.

Pros had cautioned against hurrying the method for developing a COVID-19 vaccine and stressed that it is acting in accord with the worldwide accepted norms to fasttrack vaccine development for diseases of pandemic potential.

About Author